These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 29873049)

  • 21. Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution.
    Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Isikdogan A
    Asian Pac J Cancer Prev; 2012; 13(4):1281-4. PubMed ID: 22799319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors and impact of cytotoxic second-line chemotherapy for stage IIIa-IV nonsmall lung cancer patients in China: A retrospective institution analysis of 132 patients.
    Cheng B; Cai XJ; Chen LY; Wang Z; Weng L; Li QL
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C84-8. PubMed ID: 26323932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
    Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
    Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy.
    Hirashima T; Suzuki H; Kobayashi M; Kondoh Y; Tokuoka Y; Matsuura Y; Tamiya M; Morishita N; Sasada S; Okamoto N; Akazawa K; Kawase I
    Med Oncol; 2012 Sep; 29(3):1629-37. PubMed ID: 21853345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
    Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
    Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S
    Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment.
    Zhou J; Zheng J; Zhang X; Zhao J; Zhu Y; Shen Q; Wang Y; Sun K; Zhang Z; Pan Z; Shen Y; Zhou J
    BMC Cancer; 2018 Jan; 18(1):10. PubMed ID: 29298713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
    Inal A; Kaplan MA; Kucukoner M; Urakcı Z; Kılınc F; Isıkdogan A
    Rev Port Pneumol; 2014; 20(2):62-8. PubMed ID: 24210228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.